A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
Key claim: A clinical study is evaluating the efficacy and safety of combining ruxolitinib with thalidomide in patients with myelofibrosis.
Abstract
The purpose of this study is to test any good and bad effects of the study drugs called ruxolitinib and thalidomide. Ruxolitinib and thalidomide could shrink the cancer, but it could also cause side effects.
Why this matters
Combining ruxolitinib with thalidomide revisits an immunomodulatory backbone in the cytopenic PMF niche, where ruxolitinib monotherapy is dose-constrained by anemia and thrombocytopenia. This adds to a growing landscape of ruxolitinib-combination strategies (selinexor, pelabresib, INCB057643, tasquinimod, roginolisib) addressing suboptimal JAKi response, but specifically reintroduces an inexpensive, widely available IMiD into the PMF therapeutic toolkit.